HC Wainwright Reaffirms Buy Rating for iTeos Therapeutics (NASDAQ:ITOS)

HC Wainwright restated their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS - Free Report) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $46.00 target price on the stock.

Several other analysts also recently commented on ITOS. JPMorgan Chase & Co. dropped their target price on shares of iTeos Therapeutics from $27.00 to $24.00 and set an "overweight" rating on the stock in a report on Monday, August 12th. Wedbush reaffirmed an "outperform" rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research note on Tuesday. Finally, Wells Fargo & Company began coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They issued an "overweight" rating and a $31.00 target price on the stock.

iTeos Therapeutics Trading Down 2.0 %

Shares of NASDAQ ITOS traded down $0.17 during mid-day trading on Friday, reaching $8.29. 467,503 shares of the company's stock were exchanged, compared to its average volume of 440,347. iTeos Therapeutics has a twelve month low of $7.99 and a twelve month high of $18.75. The firm has a market capitalization of $302.83 million, a price-to-earnings ratio of -2.69 and a beta of 1.39. The business has a fifty day simple moving average of $10.40 and a 200 day simple moving average of $13.99.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new position in shares of iTeos Therapeutics in the first quarter valued at $3,337,000. Clearline Capital LP acquired a new position in shares of iTeos Therapeutics during the 2nd quarter worth about $2,328,000. Candriam S.C.A. bought a new stake in shares of iTeos Therapeutics in the 2nd quarter valued at about $7,558,000. Kennedy Capital Management LLC acquired a new stake in iTeos Therapeutics in the 1st quarter valued at about $1,988,000. Finally, Dimensional Fund Advisors LP grew its holdings in iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company's stock worth $13,481,000 after purchasing an additional 117,159 shares during the period. Institutional investors and hedge funds own 97.16% of the company's stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.